Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

This study tests a combination of drugs — venetoclax (a targeted cancer pill) plus chemotherapy — for patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatment. AML is a fast-moving blood cancer, and this trial offers an option for people who have already tried standard therapies. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with AML that has relapsed (came back) or is refractory (no longer responding to treatment) - You have received at least one prior round of intensive chemotherapy or four cycles of a class of drugs called hypomethylating agents - You are in reasonably good general health (able to perform daily activities) - Your liver, kidney, and heart function meet the study's requirements **You may NOT be eligible if...** - You have had a bone marrow transplant within the last 3 months - You have active severe infections - You have significant heart, liver, or kidney problems that are not controlled - You are currently taking certain medications that could interact with the study drugs Talk to your doctor to see if this trial is right for you.